Cargando…

Renal protective effect of sacubitril/valsartan in patients with heart failure

Sacubitril/valsartan is a combined neprilysin inhibitor/angiotensin II receptor blocker designed for treatment of heart failure (HF). Nonetheless, its renal protective effect remained an issue of debate. This retrospective cohort study investigated the renal protective effect of sacubitril/valsartan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Hui-Ling, Chen, Chun-You, Chen, Cheng-Hsien, Hsu, Shih-Chang, Huang, Wen-Cheng, Sue, Yuh-Mou, Lin, Feng-Yen, Shih, Chun-Ming, Chang, Yue-Cune, Huang, Po-Hsun, Liu, Chung-Te
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907094/ https://www.ncbi.nlm.nih.gov/pubmed/33633282 http://dx.doi.org/10.1038/s41598-021-84118-8

Ejemplares similares

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
por: Chang, Po‐Cheng, et al.
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study
por: Chen, Dong-Yi, et al.
Publicado: (2021)

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
por: Niu, Chih‐Yuan, et al.
Publicado: (2022)

Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
por: Lo, Shih-Hsing, et al.
Publicado: (2021)

The Worsening Renal Perfusion Index Predicts the Prognoses of Heart Failure Patients Treated with Sacubitril/Valsartan
por: Hsu, Wan-Tseng, et al.
Publicado: (2023)

Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan
por: Yang, Tsun-Yu, et al.
Publicado: (2022)

Effects of cardiovascular medications on primary patency of hemodialysis arteriovenous fistula
por: Chang, Te-I., et al.
Publicado: (2020)

Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy
por: Huang, Hsin‐Ti, et al.
Publicado: (2022)

Study protocol for a prospective observational study to investigate the role of luminal pressure on arteriovenous fistula maturation
por: Cheng, Ho-Shun, et al.
Publicado: (2019)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
por: Hsu, Chien-Yi, et al.
Publicado: (2022)

Inhibition of β-catenin signaling attenuates arteriovenous fistula thickening in mice by suppressing myofibroblasts
por: Liu, Chung-Te, et al.
Publicado: (2022)

Luminal pressure gradient and risk of arteriovenous fistula nonmaturation
por: Kuo, Chi-Heng, et al.
Publicado: (2022)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

The influence of atrial fibrillation on the mortality of incident ESRD patients undergoing maintenance hemodialysis
por: Hsieh, Hui-ling, et al.
Publicado: (2020)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Microbial etiology of pneumonia in patients with decreased renal function
por: Chen, Chun-you, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020)

Sacubitril/Valsartan for heart failure: A protocol for systematic review and meta-analysis
por: Dai, Wenqin, et al.
Publicado: (2022)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
por: Carballo, David, et al.
Publicado: (2020)

Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert, Joseph J, et al.
Publicado: (2020)

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
por: Akbar, Sara, et al.
Publicado: (2020)

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
por: Fröhlich, Hanna, et al.
Publicado: (2022)

Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
por: Rao, Birju R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jorsr214di7pkfnm0g24kmjq3g